I-Zepatier Hepatitis C Ulwazi Lwezidakamizwa

Imithi yokwelapha inikeza amazinga aphezulu okuphulukisa ama-Gyropepe 1 and 4 Infections

Ukuhlukaniswa

I-Zepatier (elbasvir / grazoprevir) isisindo esinqunyiwe sokuhlanganiswa kwezidakamizwa esetshenziswa ekwelapheni ukutheleleka okungapheli kwe- hepatitis C (HCV) . Lezi zidakamizwa ezimbili ezibandakanya umsebenzi we-Zepatier (elbasvir, grazoprevir) ngokuvimbela kokubili amaprotheni (NS5a) ne-enzyme (NS3 / 4a protease) ibalulekile ekuphindaphindiwe kwegciwane.

I-Zepatier yamukelwa ngoJanuwari 28, 2016 yi-US Food and Drug Administration (FDA) ukuze isetshenziswe kubantu abadala kweminyaka engu-18 noma ngaphezulu nge- HCV genotype 1 noma 4 ukutheleleka , kufaka nalabo abane-cirrhosis.

Kuvunyelwe ukusetshenziswa kokubili okungaphathwa kabi (ukwelashwa-naïve) noma iziguli ezilashwa ngaphambili (iziguli ezithintekayo), ngokuya nge-genotype ye-HCV kanye nesimo sokwelapha.

Ukusebenza

I-Zepatier ibikwa ukuthi inezibalo eziphuthumayo zokwelashwa eSigabeni II sokuhlolwa kwabantu. Ukuphulukiswa kwe-HCV kuchazwa njengokulondoloza umthamo wegciwane elingenakulinganiswa kwamasonto angu-24 ngemva kokuphela kwelashwa (eyaziwa ngokuthi impendulo ye-virologic eqhubekayo, noma i-SVR ).

Izinga le-SVR jikelele lalingu-94% kuya ku-97% ezigulini ezine-HCV genotype 1 ukutheleleka, kanti iziguli ezine-genotype 4 zibhekwe ukuthi zinezibalo ze-SVR zika-97% kuya ku-100%.

Isilinganiso

Ithebhulethi eyodwa (50mg / 100mg) ithathwe nsuku zonke noma ngaphandle kokudla. Amaphilisi e-Zepatier ane-oval-shaped, beige-colored nefilimu-enemibala, ene "770" embossed ngakolunye uhlangothi.

Ukubeka izincomo

I-Zepatier inqunywe noma ngaphandle kwe-ribavirin ye-genotype 1 noma 4 ukutheleleka. Ngokungafani nemithi yokwelapha ye-HCV eyedlule, i- peginterferon (isidakamizwa esihlobene nomphumela ovame ukungenakubekezelelwa) asidingeki.

Ngaphambi kokuqala ukwelashwa, ukuhlolwa kofuzo kungenziwa ukuze kunqume ukuthi unayo yini uhlobo lwegciwane elingavumelani ne-elbasvir ingxenye ye-Zepatier (eyaziwa ngokuthi i-polymorphism ehambisana ne-NS5a).

Ubude besikhathi semishanguzo yokwelashwa kusuka emavikini angu-12 kuya ku-16, kuye ngokuthi i-HCV genotype nesimo sokwelashwa.

I-Genotype Isimo sokwelashwa Kuthathwa
i-ribavirin?
Isikhathi
I-Genotype 1a ukwelashwa-naïve ngaphandle kwe- elbasvir-resistant
igciwane
cha Amaviki angu-12
ukwelashwa-naïve nge- elbasvir-ukumelana
igciwane
Yebo Amaviki angu-16
ngaphambili ephathwa nge-ribavirin +
i-peginterferon ngaphandle kwe -virus e-elbasvir-resistant
cha Amaviki angu-12
ngaphambili ephathwa nge-ribavirin +
i-peginterferon ne- elbasvir-resistant virus
Yebo Amaviki angu-16
ngaphambili ephathwa nge-ribavirin +
i-peginterferon + i-HCV protease inhibitor
Yebo Amaviki angu-12
I-Genotype 1b ukwelashwa-naïve cha Amaviki angu-12
ngaphambili ephathwa nge-ribavirin +
i-peginterferon
cha
Amaviki angu-12
ngaphambili ephathwa nge-ribavirin +
i-peginterferon + i-HCV protease inhibitor *
Yebo Amaviki angu-12
I-Genotype 4 ukwelashwa-naïve cha Amaviki angu-12
ngaphambili ephathwa nge-ribavirin +
i-peginterferon
Yebo Amaviki angu-16

* - I- Olysio (simeprevir), i-Victrelis (boceprevir), i-Incivek (i-telaprevir)

Imiphumela Ejwayelekile Ejwayelekile

Imiphumela emibi kakhulu ehlobene nokusetshenziswa kwe-Zepatier (eyenzeka ngeziguli ezingaphezu kuka-5%) yilezi:

Uma isetshenziswe nge-ribavirin, imiphumela emibi yokwelashwa ebikwa kakhulu (eyenzeka ngeziguli ezingaphezu kuka-5%) ifaka:

Ukusebenzisana kwezidakamizwa

Imithi elandelayo akufanele isetshenziswe uma ithatha i-Zepatier ngoba ingabangela ukusebenzisana okukhulu kwezidakamizwa-izidakamizwa:

Ukucatshangelwa Ukwelashwa

Kuye kwabikwa ezifundweni zokwelashwa ukuthi i-1% yeziguli eziseZepatier zakhuphuka kakhulu ezinozini ze-enzyme zesibindi ezibonisa ubuthi obubangelwa isibindi, ngokuvamile noma emva kweviki lesishiyagalombili yokwelapha. Ngakho-ke, ukuhlolwa kwegazi okuhambisana nesibindi kuyadingeka ngaphambi kokuqala ukwelashwa njalo njalo phakathi ne-HCV yokwelashwa.

I-Zepatier akumele inqunywe iziguli ezinokukhubazeka okukhulu kwesibindi.

Ukusetshenziswa kwe-ribavirin kunqatshelwe ekukhulelweni futhi akufanele kunqunywe noma nge-Zepatier noma noma yikuphi omunye umuthi we-hepatitis C. Iziguli ezibhekene ne-ribavirin kufanele zelulelwe ukuba zigweme ukukhulelwa futhi zisebenzise okungenani izindlela ezimbili ezingekho ze-hormonal zokuvimbela ukukhulelwa ngesikhathi sokulashwa kanye nezinyanga eziyisithupha emva kokuqedwa kwelashwa.

Umthombo:

I-US Food and Drug Administration (FDA). "I-FDA ivumela i-Zepatier ukuthi ilashwe isifo esingenasifo sohlobo lwe-hepatitis C esingama-1 no-4." I-Silver Spring, e-Maryland; ukushicilelwa okukhishwe ngoJanuwari 28, 2016.

Merck. "I-Zepatier - Amaphuzu avelele ekuchazeni ulwazi." IKenilworth, eNew Jersey; kufinyelelwe ngoJanuwari 29, 2016.